Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
Novel angiotensin-converting enzyme (ACE) inhibitory peptides were identified from whey protein hydrolysates (WPH) in vitro in our previous study and the antihypertensive abilities of WPH in vivo were further investigated in the current study. Results indicated that WPH significantly inhibited the development of high blood pressure and tissue injuries caused by hypertension. WPH inhibited ACE activity (20.81%, P < 0.01), and reduced renin concentration (P < 0.05), thereby reducing systolic blood pressure (SBP) (12.63%, P < 0.05) in spontaneously hypertensive rats. The increased Akkermansia, Bacteroides, and Lactobacillus abundance promoted high short chain fatty acid content in feces after WPH intervention. These changes jointly contributed to low blood pressure. The heart weight and cardiomyocyte injuries (hypertrophy and degeneration) were alleviated by WPH. The proteomic results revealed that 19 protein expressions in the heart mainly associated with the wingless/integrated (Wnt) signaling pathway and Apelin signaling pathway were altered after WPH supplementation. Notably, WPH alleviated serum oxidative stress, indicated by the decreased malondialdehyde content (P < 0.01), enhanced total antioxidant capacity (P < 0.01) and superoxide dismutase activity (P < 0.01). The current study suggests that WPH exhibit promising antihypertensive abilities in vivo and could be a potential alternative for antihypertensive dietary supplements.
M. Yildiz, A.A. Oktay, M.H. Stewart, et al., Left ventricular hypertrophy and hypertension, Prog. Cardiovasc. Dis. 63 (2020) 10-21. https://doi.org/10.1016/j.pcad.2019.11.009.
A. Verma, S.D. Solomon, Diastolic dysfunction as a link between hypertension and heart failure, Med. Clin. N. Am. 93 (2009) 647-664. https://doi.org/10.1016/j.mcna.2009.02.013.
P.M. Kearney, M. Whelton, K. Reynolds, et al., Global burden of hypertension: analysis of worldwide data, The Lancet 365 (2005) 217-223. https://doi.org/10.1016/S0140-6736(05)17741-1.
C. Wang, Y. Yuan, M.Y. Zheng, et al., Association of age of onset of hypertension with cardiovascular diseases and mortality, J. Am. Coll. Cardiol. 75 (2020) 2921-2930. https://doi.org/10.1016/j.jacc.2020.04.038.
M. Volpe, A. Battistoni, D. Chin, et al., Renin as a biomarker of cardiovascular disease in clinical practice, Nutr. Metab. Cardiovasc. Dis. 22 (2012) 312-317. https://doi.org/10.1016/j.numecd.2011.12.006.
A.R. Gunkel, K.H. Thurner, G. Kanonier, et al., Angioneurotic edema as a reaction to angiotensin-converting enzyme inhibitors, Am. J. Otolaryngol. 17 (1996) 87-91. https://doi.org/10.1016/S0196-0709(96)90001-0.
T. Yang, M.M. Santisteban, V. Rodriguez, et al., Gut dysbiosis is linked to hypertension, Hypertension 65 (2015) 1331-1340. https://doi.org/10.1161/HYPERTENSIONAHA.115.05315.
S. Adnan, J.W. Nelson, N.J. Ajami, et al., Alterations in the gut microbiota can elicit hypertension in rats, Physiol Genomics. 49 (2017) 96-104. https://doi.org/10.1152/physiolgenomics.00081.2016.
M. Toral, I. Robles-Vera, N. de la Visitación, et al., Role of the immune system in vascular function and blood pressure control induced by faecal microbiota transplantation in rats, Acta Physiol. 227 (2019) e13285. https://doi.org/10.1111/apha.13285.
F. Yang, H.W. Chen, Y.H. Gao, et al., Gut microbiota-derived short-chain fatty acids and hypertension: mechanism and treatment, Biomed. Pharmacother. 130 (2020) 110503. https://doi.org/10.1016/j.biopha.2020.110503.
S. Kim, R. Goel, A. Kumar, et al., Imbalance of gut microbiome and intestinal epithelial barrier dysfunction in patients with high blood pressure, Clin. Sci. 132 (2018) 701-718. https://doi.org/10.1042/CS20180087.
J. Pluznick, A novel SCFA receptor, the microbiota, and blood pressure regulation, Gut Microbes. 5 (2014) 202-207. https://doi.org/10.4161/gmic.27492.
F. Ndiaye, T. Vuong, J. Duarte, et al., Anti-oxidant, anti-inflammatory and immunomodulating properties of an enzymatic protein hydrolysate from yellow field pea seeds, Eur. J. Nutr. 51 (2012) 29-37. https://doi.org/10.1007/s00394-011-0186-3.
A. Kaur, B.A. Kehinde, P. Sharma, et al., Recently isolated food-derived antihypertensive hydrolysates and peptides: a review, Food Chem. 346 (2021) 128719. https://doi.org/10.1016/j.foodchem.2020.128719.
Y. Etemadian, V. Ghaemi, A.R. Shaviklo, et al., Development of animal/ plant-based protein hydrolysate and its application in food, feed and nutraceutical industries: state of the art, J. Clean. Prod. 278 (2021) 123219. https://doi.org/10.1016/j.jclepro.2020.123219.
R. Vásquez-Villanueva, J.M. Orellana, M.L. Marina, et al., Isolation and characterization of angiotensin converting enzyme inhibitory peptides from peach seed hydrolysates: in vivo assessment of antihypertensive activity, J. Agric. Food Chem. 67 (2019) 10313-10320. https://doi.org/10.1021/acs.jafc.9b02213.
F. Lin, L. Chen, R. Liang, et al., Pilot-scale production of low molecular weight peptides from corn wet milling byproducts and the antihypertensive effects in vivo and in vitro, Food Chem. 124 (2011) 801-807. https://doi.org/10.1016/j.foodchem.2010.06.099.
S.J. Lee, Y.S. Kim, S.E. Kim, et al., Purification and characterization of a novel angiotensin I-converting enzyme inhibitory peptide derived from an enzymatic hydrolysate of duck skin byproducts, J. Agric. Food Chem. 60 (2012) 10035-10040. https://doi.org/10.1021/jf3023172.
C. Zhang, Y.Q. Zhang, Z.Y. Wang, et al., Production and identification of antioxidant and angiotensin-converting enzyme inhibition and dipeptidyl peptidase Ⅳ inhibitory peptides from bighead carp (Hypophthalmichthys nobilis) muscle hydrolysate, J. Funct. Foods 35 (2017) 224-235. https://doi.org/10.1016/j.jff.2017.05.032.
J.G. dos Santos Aguilar, H.H. Sato, Microbial proteases: production and application in obtaining protein hydrolysates, Food Res. Int. 103 (2018) 253-262. https://doi.org/10.1016/j.foodres.2017.10.044.
A. Brandelli, D.J. Daroit, A.P.F. Corrêa, Whey as a source of peptides with remarkable biological activities, Food Res. Int. 73 (2015) 149-161. https://doi.org/10.1016/j.foodres.2015.01.016.
F.S. Fajardo-Espinoza, C. Ordaz-Pichardo, U. Sankar, et al., In vitro cytomodulatory and immunomodulatory effects of bovine colostrum whey protein hydrolysates, Int. J. Food Sci. Technol. 56 (2021) 2109-2121. https://doi.org/10.1111/ijfs.14767.
X.Y. Li, C.S. Feng, H. Hong, et al., Novel ACE inhibitory peptides derived from whey protein hydrolysates: identification and molecular docking analysis, Food Biosci. 48 (2022) 101737. https://doi.org/10.1016/j.fbio.2022.101737.
E. Arranz, A.R. Corrochano, C. Shanahan, et al., Antioxidant activity and characterization of whey protein-based beverages: effect of shelf life and gastrointestinal transit on bioactivity, Innov. Food Sci. Emerg. 57 (2019) 102209. https://doi.org/10.1016/j.ifset.2019.102209.
K. Wang, Z.X. Fu, X.Y. Li, et al., Whey protein hydrolysate alleviated atherosclerosis and hepatic steatosis by regulating lipid metabolism in apoE−/− mice fed a Western diet, Food Res. Int. 157 (2022) 111419. https://doi.org/10.1016/j.foodres.2022.111419.
K. Ishiguro, Y. Sameshima, T. Kume, et al., Hypotensive effect of a sweetpotato protein digest in spontaneously hypertensive rats and purification of angiotensin I-converting enzyme inhibitory peptides, Food Chem. 131 (2012) 774-779. https://doi.org/10.1016/j.foodchem.2011.09.038.
R. He, Y.J. Wang, Y.J. Yang, et al., Rapeseed protein-derived ACE inhibitory peptides LY, RALP and GHS show antioxidant and anti-inflammatory effects on spontaneously hypertensive rats, J. Funct. Foods 55 (2019) 211-219. https://doi.org/10.1016/j.jff.2019.02.031.
J. Chen, W. Duan, X. Ren, et al., Effect of foxtail millet protein hydrolysates on lowering blood pressure in spontaneously hypertensive rats, Eur. J. Nutr. 56 (2017) 2129-2138. https://doi.org/10.1007/s00394-016-1252-7.
Q. Zhou, J. Wu, J. Tang, et al., Beneficial effect of higher dietary fiber intake on plasma HDL-C and TC/HDL-C ratio among Chinese rural-to-urban migrant workers, Int. J. Environ. Res. Public Health 12 (2015) 4726-4738. https://doi.org/10.3390/ijerph120504726.
J.Y. Zhang, J. Yu, Y. Chen, et al., Exogenous hydrogen sulfide supplement attenuates isoproterenol-induced myocardial hypertrophy in a sirtuin 3-dependent manner, Oxid. Med. Cell. Longev. 2018 (2018) e9396089. https://doi.org/10.1155/2018/9396089.
G. Matute-Bello, G. Downey, B.B. Moore, et al., An official American thoracic society workshop report: features and measurements of experimental acute lung injury in animals, Am. J. Respir. Cell Mol. Biol. 44 (2011) 725-738. https://doi.org/10.1165/rcmb.2009-0210ST.
E.B. Selçuk, M. Sungu, H. Parlakpinar, et al., Evaluation of the cardiovascular effects of varenicline in rats, Drug Des. 9 (2015) 5705-5717. https://doi.org/10.2147/DDDT.S92268.
Y.F. Liang, H.J. Zhang, L. Tian, et al., Gut microbiota and metabolic profile as affected by Maillard reaction products derived from bighead carp meat hydrolysates with galactose and galacto-oligosaccharides during in vitro pig fecal fermentation, Food Chem. 398 (2023) 133905. https://doi.org/10.1016/j.foodchem.2022.133905.
S.S. Hu, C.H. Hu, L.Y. Luo, et al., Pu-erh tea increases the metabolite Cinnabarinic acid to improve circadian rhythm disorder-induced obesity, Food Chem. 394 (2022) 133500. https://doi.org/10.1016/j.foodchem.2022.133500.
X. Wang, L. Wang, X. Cheng, et al., Hypertension-attenuating effect of whey protein hydrolysate on spontaneously hypertensive rats, Food Chem. 134 (2012) 122-126. https://doi.org/10.1016/j.foodchem.2012.02.074.
O. Abdelhedi, M. Nasri, Basic and recent advances in marine antihypertensive peptides: production, structure-activity relationship and bioavailability, Trends Food Sci. Tech. 88 (2019) 543-557. https://doi.org/10.1016/j.tifs.2019.04.002.
T. Yang, V. Aquino, G.O. Lobaton, et al., Sustained captopril-induced reduction in blood pressure is associated with alterations in gut-brain axis in the spontaneously hypertensive rat, J. Am. Heart Assoc. 8 (2019) e010721. https://doi.org/10.1161/JAHA.118.010721.
B.S. Heran, M.M. Wong, I.K. Heran, et al., Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension, Cochrane Db. Syst. Rev. 4 (2008). https://doi.org/10.1002/14651858.CD003823.pub2.
O. Power, A. Fernández, R. Norris, et al., Selective enrichment of bioactive properties during ultrafiltration of a tryptic digest of β-lactoglobulin, J. Funct. Foods 9 (2014) 38-47. https://doi.org/10.1016/j.jff.2014.04.002.
L.C. Pinheiro, J.E. Tanus-Santos, M.M. Castro, The potential of stimulating nitric oxide formation in the treatment of hypertension, Expert Opin. Ther. Targets 21 (2017) 543-556. https://doi.org/10.1080/14728222.2017.1310840.
M.B. O’Keeffe, R.J. FitzGerald, Whey protein hydrolysate induced modulation of endothelial cell gene expression, J. Funct. Foods 40 (2018) 102-109. https://doi.org/10.1016/j.jff.2017.11.001.
L. te Riet, J.H.M. van Esch, A.J.M. Roks, et al., Hypertension: renin-angiotensin-aldosterone system alterations, Circ. Res. 116 (2015) 960-975. https://doi.org/10.1161/CIRCRESAHA.116.303587.
J. de Champlain, R. Wu, H. Girouard, et al., Oxidative stress in hypertension, Clin. Exp. Hypertens. A 26 (2004) 593-601. https://doi.org/10.1081/CEH-200031904.
S. Sharma, G. Ruffenach, S. Umar, et al., Role of oxidized lipids in pulmonary arterial hypertension, Pulm. Circ. 6 (2016) 261-273. https://doi.org/10.1086/687293.
S. Ogura, T. Shimosawa, Oxidative stress and organ damages, Curr. Hypertens. Rep. 16 (2014) 452. https://doi.org/10.1007/s11906-014-0452-x.
X. Peng, Y.L. Xiong, B. Kong, Antioxidant activity of peptide fractions from whey protein hydrolysates as measured by electron spin resonance, Food Chem. 113 (2009) 196-201. https://doi.org/10.1016/j.foodchem.2008.07.068.
X.C. Yu, Z. Li, X.R. Liu, et al., The antioxidant effects of whey protein peptide on learning and memory improvement in aging mice models, Nutrients 13 (2021) 2100. https://doi.org/10.3390/nu13062100.
I. Saito, K. Yamagishi, Y. Kokubo, et al., Association of high-density lipoprotein cholesterol concentration with different types of stroke and coronary heart disease: The Japan Public Health Center-based prospective (JPHC) study, Atherosclerosis 265 (2017) 147-154. https://doi.org/10.1016/j.atherosclerosis.2017.08.032.
D. Andrzejczak, D. Górska, The effects of celiprolol on serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats, Pharmacol. Rep. 66 (2014) 68-73. https://doi.org/10.1016/j.pharep.2013.08.006.
A. Mantovani, G. Zoppini, G. Targher, et al., Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive type 2 diabetic individuals, J. Endocrinol. Invest. 35 (2012) 215-218. https://doi.org/10.1007/BF03345421.
S.P. Cartland, N. Tamer, M.S. Patil, et al., A “Western Diet” promotes symptoms of hepatic steatosis in spontaneously hypertensive rats, Int. J. Exp. Pathol. 101 (2020) 152-161. https://doi.org/10.1111/iep.12369.
R.J.F. Felizardo, I.K.M. Watanabe, P. Dardi, et al., The interplay among gut microbiota, hypertension and kidney diseases: the role of short-chain fatty acids, Pharmacol. Res. 141 (2019) 366-377. https://doi.org/10.1016/j.phrs.2019.01.019.
J. De la Cuesta-Zuluaga, N.T. Mueller, R. Álvarez-Quintero, et al., Higher fecal short-chain fatty acid levels are associated with gut microbiome dysbiosis, obesity, hypertension and cardiometabolic disease risk factors, Nutrients 11 (2019) 51. https://doi.org/10.3390/nu11010051.
F.Z. Marques, C.R. Mackay, D.M. Kaye, Beyond gut feelings: how the gut microbiota regulates blood pressure, Nat. Rev. Cardiol. 15 (2018) 20-32. https://doi.org/10.1038/nrcardio.2017.120.
E.S. Chambers, T. Preston, G. Frost, et al., Role of gut microbiota-generated short-chain fatty acids in metabolic and cardiovascular health, Curr. Nutr. Rep. 7 (2018) 198-206. https://doi.org/10.1007/s13668-018-0248-8.
V. Karoor, D. Strassheim, T. Sullivan, et al., The short-chain fatty acid butyrate attenuates pulmonary vascular remodeling and inflammation in hypoxia-induced pulmonary hypertension, Int. J. Mol. Sci. 22 (2021) 9916. https://doi.org/10.3390/ijms22189916.
H. Bartolomaeus, A. Balogh, M. Yakoub, et al., Short-chain fatty acid propionate protects from hypertensive cardiovascular damage, Circulation 139 (2019) 1407-1421. https://doi.org/10.1161/CIRCULATIONAHA.118.036652.
M.S. Madhur, H.E. Lob, L.A. McCann, et al., Interleukin 17 promotes angiotensin Ⅱ-induced hypertension and vascular dysfunction, Hypertension 55 (2010) 500-507. https://doi.org/10.1161/HYPERTENSIONAHA.109.145094.
I. Robles-Vera, M. Toral, J. Duarte, Microbiota and hypertension: role of the sympathetic nervous system and the immune system, Am. J. Hypertens. 33 (2020) 890-901. https://doi.org/10.1093/ajh/hpaa103.
M. Luu, S. Pautz, V. Kohl, et al., The short-chain fatty acid pentanoate suppresses autoimmunity by modulating the metabolic-epigenetic crosstalk in lymphocytes, Nat. Commun. 10 (2019) 760. https://doi.org/10.1038/s41467-019-08711-2.
S. Ghosh, W. He, J. Gao, et al., Whole milk consumption is associated with lower risk of coronary artery calcification progression: evidences from the Multi-Ethnic Study of Atherosclerosis, Eur. J. Nutr. 60 (2021) 1049-1058. https://doi.org/10.1007/s00394-020-02301-5.
M. Hecker, N. Sommer, H. Voigtmann, et al., Impact of short-and medium-chain fatty acids on mitochondrial function in severe inflammation, J. Parenter. Enteral Nutr. 38 (2014) 587-594. https://doi.org/10.1177/0148607113489833.
P. Louis, H.J. Flint, Formation of propionate and butyrate by the human colonic microbiota, Environ. Microbiol. 19 (2017) 29-41. https://doi.org/10.1111/1462-2920.13589.
J.L. Rico, K.F. Reardon, S.K. De Long, Inoculum microbiome composition impacts fatty acid product profile from cellulosic feedstock, Bioresour. 323 (2021) 124532. https://doi.org/10.1016/j.biortech.2020.124532.
R.A. Corb Aron, A. Abid, C.M. Vesa, et al., Recognizing the benefits of pre-/probiotics in metabolic syndrome and type 2 diabetes mellitus considering the influence of Akkermansia muciniphila as a key gut bacterium, Microorganisms 9 (2021) 618. https://doi.org/10.3390/microorganisms9030618.
H. Yu, L. Qin, H. Hu, et al., Alteration of the gut microbiota and its effect on AMPK/NADPH oxidase signaling pathway in 2K1C rats, Biomed. Res. Int. 2019 (2019) 8250619. https://doi.org/10.1155/2019/8250619.
J. Li, F. Zhao, Y. Wang, et al., Gut microbiota dysbiosis contributes to the development of hypertension, Microbiome 5 (2017) 14. https://doi.org/10.1186/s40168-016-0222-x.
M. Gómez-Guzmán, M. Toral, M. Romero, et al., Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats, Mol. Nutr. Food Res. 59 (2015) 2326-2336. https://doi.org/10.1002/mnfr.201500290.
P. Malekar, M. Hagenmueller, A. Anyanwu, et al., Wnt signaling is critical for maladaptive cardiac hypertrophy and accelerates myocardial remodeling, Hypertension 55 (2010) 939-945. https://doi.org/10.1161/HYPERTENSIONAHA.109.141127.
H.J. Chun, Z.A. Ali, Y. Kojima, et al., Apelin signaling antagonizes Ang Ⅱ effects in mouse models of atherosclerosis, J. Clin. Invest. 118 (2008) 3343-3354. https://doi.org/10.1172/JCI34871.
H. Nguyen, V.L. Chiasson, P. Chatterjee, et al., Interleukin-17 causes Rho-kinase-mediated endothelial dysfunction and hypertension, Cardiovasc. Res. 97 (2013) 696-704. https://doi.org/10.1093/cvr/cvs422.
A. Schäfer, J. Widder, M. Eigenthaler, et al., Reduced basal nitric oxide bioavailability and platelet activation in young spontaneously hypertensive rats, Biochem. Pharmacol. 67 (2004) 2273-2279. https://doi.org/10.1016/j.bcp.2004.02.034.
T.D. Giles, Aspects of nitric oxide in health and disease: a focus on hypertension and cardiovascular disease, J. Clin. Hypertens. 8 (2006) 2-16. https://doi.org/10.1111/j.1524-6175.2006.06023.x.
1009
Views
133
Downloads
2
Crossref
3
Web of Science
3
Scopus
0
CSCD
Altmetrics
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).